Rs 12,000 crore magic pill race begins to shrink India's pot bellies. Which pharma stocks will win GLP-1 w

India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly lower prices. Analysts predict the market will reach Rs 12,000 crore in five years. This expansion targets millions of diabetics and obese individuals. Companies are competing with innovative pricing and product offerings, promising wider access to these crucial treatments.